In the last 10 years, psychiatric interest in the use of psychedelics, such as psilocybin and LSD, has surged. A new study employed mice to examine how LSD could exert changes on the inflammatory response and the gut microbiome.
Lab grown brains help to shed insight on 5-MeO-DMT mechanisms.
What is known about the divergent roles of the microscopic targets within the cardiovascular system and the cardiac risks versus benefits of psychedelics?
By engineering E. coli to produce norbaeocystin, researchers seek to settle whether this precursor to psilocybin is itself psychedelic.
Psychedelics have demonstrated the potential for rapid, dramatic, and enduring therapeutic effects in people with psychiatric disorders as well as in animal models of these conditions. However, the molecular adaptations in the brain that underlie these profound psychedelic-induced behavioral changes have yet to be defined.
As science unravels ketamine’s mechanisms of action to better understand its efficacy as an antidepressant, its antibacterial activity has been probed at the same time. Current research has found a naturally-occurring, fungal origin for the drug, exhibiting antiparasitic properties.
As ketamine’s demonstrable therapeutic applications have become ever more popular, earlier research lauding its potential as an antimicrobial and antiparasitic agent has quietly reemerged.
Relatively unknown to Western medicine, Kambô is a frog skin secretion with potent, and potentially dangerous physiological and psychological effects.
Dr. Rachel Yehuda shares details about an ongoing clinical trial involving MDMA-assisted psychotherapy to treat post-traumatic stress disorder in veterans.
The therapeutic uses of psychedelics were discovered over 6,000 years ago, but recent scientific exploration brings them to the mainstream.